WILEX is a biopharmaceutical company focused on targeted therapies in oncology. The stock listed WILEX AG is acting exclusively as a holding company. Operations are focused on the R&D activities of the fully owned subsidiary Heidelberg Pharma GmbH in Ladenburg.
Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. Amanitin is a member of the amatoxin group of natural poisons, which includes the death cap mushroom (Amanita phalloides). Amanitin inhibits RNA polymerase II which results in programmed cell death (apoptosis). Using an Antibody Drug Conjugate (ADC) technology, this highly effective agent Amanitin will be coupled via a chemical linker with different antibodies. This proprietary technology platform is being applied to develop the company’s own therapeutic antibody drug conjugates as well as in third-party collaborations to create a variety of ATAC candidates.
The goal is to develop proprietary ATACs and prepare them for early clinical development. In Fall 2016, Heidelberg Pharma selected a lead candidate, HDP-101, which consists of a BCMA antibody, a specific linker and Amanitin. Preparations for the formal non-clinical as well as clinical development of HDP-101 have been started. The Company expects to enter the clinic in 2018.
In addition, Heidelberg Pharma offers preclinical services with a focus on explorative pharmacology in oncology, autoimmunity and inflammation for pharma and biotech companies.
WILEX AG’s clinical R&D projects will only be further developed in cooperation with licensing partners. The drug candidate MESUPRON® has been out-licensed to two partners for further development and subsequent marketing. The diagnostic and therapeutic drug candidates REDECTANE® and RENCAREX® are available for out-licensing.
WILEX is listed on the Frankfurt Stock Exchange.